On March 1, 2022, Vivos Therapeutics, Inc. (the Company), with the unanimous approval of the Board of Directors of the Company, provided Dr. G. Dave Singh, the Company's Chief Medical Officer (Dr. Singh), with notice of termination of his employment with the Company for cause pursuant to the terms Dr. Singh's employment agreement with the Company, dated October 9, 2020. As such, Dr. Singh is no longer affiliated with the Company effective March 1, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.63 USD | +3.79% | +2.33% | -78.86% |
01/04 | Signs of Softening Inflation Fuel Narrow Premarket Gains for US Equity Futures | MT |
01/04 | Top Premarket Decliners | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-78.86% | 7.56M | |
+73.17% | 12.37B | |
-18.08% | 7.96B | |
+16.24% | 7.09B | |
+3.39% | 5.83B | |
+11.77% | 5.35B | |
+29.65% | 4.63B | |
-17.74% | 4B | |
-35.34% | 2.41B | |
+2.10% | 2B |
- Stock Market
- Equities
- VVOS Stock
- News Vivos Therapeutics, Inc.
- Vivos Therapeutics, Inc. Announces Termination of G. Dave Singh, Chief Medical Officer